Finance

Healthcare active runners: Galena Biopharma Inc (NASDAQ:GALE), Bristol-Myers Squibb (NYSE:BMY), Idera Pharmaceuticals Inc (NASDAQ:IDRA), EXACT Sciences Corporation (NASDAQ:EXAS)

Trade-Ideas LLC identified Galena Biopharma Inc (NASDAQ:GALE) as a “dead cat bounce” (down big yesterday but up big today) candidate. TheStreet Quant Ratings rates Galena Biopharma Inc (NASDAQ:GALE) as a sell. Galena Biopharma Inc (NASDAQ:GALE) stock performance was 12.61% in last session and finished the day at $2.50. Traded volume was 6.16million shares in the last session and the average volume of the stock remained 8.70million shares. The beta of the stock remained 0.82. Galena Biopharma Inc (NASDAQ:GALE) insider ownership is 0.50%.

The 17th annual Oral, Head and Neck Cancer Awareness Week will be held April 20 – 26, 2014. Bristol-Myers Squibb Co (NYSE:BMY) has provided funding for free screenings as part of the company’s support of OHANCAW. Bristol-Myers Squibb Co (NYSE:BMY) rose 0.25 percent to $51.95 Monday on volume of 6.77million shares. The intra-day range of the stock was $51.70 to $52.30. Bristol-Myers Squibb Co (NYSE:BMY) has a market capitalization of $86.08billion.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) shares jumped 17.78% after the company announced positive top-line data from a phase II study on its lead pipeline candidate, IMO-8400, an antagonist of toll-like receptors (TLRs) 7, 8, and 9. Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s stock on Mar 31, 2014 reported a decrease of -10.72% to the closing price of $4.08. Its fifty two weeks range is $0.43 -$6.87. The total market capitalization recorded $336.03million. The overall volume in the last trading session was 6.83million shares. In its share capital, IDRA has 82.36million outstanding shares.

Exact Sciences Corporation (NASDAQ:EXAS) said Thursday afternoon that a U.S. Food and Drug Administration advisory panel has unanimously approved its DNA-based, noninvasive colon cancer screening test, paving the way for potential market approval. On Monday, shares of EXACT Sciences Corporation (NASDAQ:EXAS) advanced 10.19% to close the day at $14.17. Company return on investment (ROI) is -33.50% and its monthly performance is recorded as 5.35%. EXACT Sciences Corporation (NASDAQ:EXAS) quarterly revenue growth is 17.50%.